Get the Stockscreener App
1.255
2.47%
0.035
Tevogen Bio Holdings Inc stock is traded at $1.255, with a volume of 152.40K.
It is up +2.47% in the last 24 hours and up +10.63% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
See More
Previous Close:
$1.22
Open:
$1.22
24h Volume:
152.40K
Relative Volume:
0.18
Market Cap:
$228.03M
Revenue:
-
Net Income/Loss:
$52.50M
P/E Ratio:
43.13
EPS:
0.0291
Net Cash Flow:
$-4.13M
1W Performance:
-6.71%
1M Performance:
+10.63%
6M Performance:
+45.33%
1Y Performance:
+56.71%
1-Day Range:
$1.20
$1.26
1-Week Range:
$1.20
$1.355
52-Week Range:
$0.2556
$3.09
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Compare TVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.2548 | 228.03M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.28 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.57 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.58 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Tevogen Uses AI To Advance EBV-Specific T Cell Therapy Toward Clinical Trials - Nasdaq
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery - GlobeNewswire
Breakthrough: AI Technology Accelerates EBV Cancer Treatment Discovery at Tevogen - Stock Titan
Tevogen Bio (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital - Defense World
Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives - Nasdaq
Tevogen expands headquarters in Warren, New Jersey - Yahoo Finance
Tevogen’s lease agreement will double headquarters footprint at Warren HQ - ROI-NJ
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives - The National Law Review
Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft - Nasdaq
Tevogen Transforms into AI Powerhouse: $36B Revenue Target as Company Doubles HQ Size - Stock Titan
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Shares Purchased by Northern Trust Corp - Defense World
tevogen bio expands office lease in new jersey with key amendment - Investing.com Canada
Tevogen Bio Expands Office Space in New Jersey - TipRanks
Tevogen Bio expands AI in immunotherapy development By Investing.com - Investing.com South Africa
Tevogen Bio expands AI in immunotherapy development - Investing.com India
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships - The Manila Times
Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies - Nasdaq
Tevogen Details its Artificial Intelligence Initiative, - GlobeNewswire
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered ... - Bluefield Daily Telegraph
Tevogen Teams Up with Microsoft to Transform Healthcare: New AI Platform Targets $5T Industry - Stock Titan
Tariff Twist and PCE Ahead—Markets Hold Key Support - The Globe and Mail
This Raytheon Rival Is on Track to Hit New 52-Week Highs - The Globe and Mail
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla - The Globe and Mail
Is IonQ Stock a Buy Now? - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Sees Large Drop in Short Interest - Defense World
4 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Globe and Mail
Tevogen Peports Plans to Increase the Target Population for TVGN 489 - Insider Monkey
Tevogen expands target for COVID treatment to seniors By Investing.com - Investing.com India
Tevogen expands target for COVID treatment to seniors - Investing.com Australia
Tevogen Bio Plans to Expand Specialty Care Pipeline to - GlobeNewswire
Tevogen to Update on Robust Portfolio Assets, Business - GlobeNewswire
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting - The Manila Times
Tevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025 - Nasdaq
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited ... - Bluefield Daily Telegraph
Tevogen Unveils Massive $10B Portfolio Valuation and AI Expansion Ahead of Critical June Meeting - Stock Titan
Nvidia-Foxconn AI Alliance Could Disrupt the Supercomputer Market—What’s at Stake for Investors - The Globe and Mail
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock Position Raised by Barclays PLC - Defense World
Tevogen Bio Holdings Inc. SEC 10-Q Report - TradingView
Tevogen Bio (NASDAQ:TVGN) Given “Buy” Rating at D. Boral Capital - Defense World
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - The Manila Times
Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition - Nasdaq
JPMorgan Chase & Co. Has $40,000 Stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) - Defense World
Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - ADVFN
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - The Globe and Mail
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):